INIvan Pereira Nascimento

Ivan Pereira Nascimento

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ivan Pereira Nascimento has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recombinant BCG-LTAK63 Vaccine Candidate for Tuberculosis Induces an Inflammatory Profile in Human Macrophages

    by Carina C. dos Santos, Kimberley V. Walburg, Suzanne van Veen, Louis G. Wilson, Carlos E. M. Trufen, Ivan P. Nascimento, Tom H. M. Ottenhoff, Luciana C. C. Leite, Mariëlle C. Haks

    Tuberculosis (TB) is one of the top 10 leading causes of death worldwide. The recombinant BCG strain expressing the genetically detoxified A subunit of the thermolabile toxin from Escherichia coli (LTAK63) adjuvant (rBCG-LTAK63) has previously been shown to confer superior protection and immunogenicity compared to BCG in a murine TB infection model. To further investigate the immunological mechanisms induced by rBCG-LTAK63, we evaluated the immune responses induced by rBCG-LTAK63, BCG, and Mycobacterium tuberculosis (Mtb) H37Rv strains in experimental infections of primary human M1 and M2 macrophages at the transcriptomic and cytokine secretion levels. The rBCG-LTAK63-infected M1 macrophages more profoundly upregulated interferon-inducible genes such as IFIT3, OAS3, and antimicrobial gene CXCL9 compared to BCG, and induced higher levels of inflammatory cytokines such as IL-12(p70), TNF-β, and IL-15. The rBCG-LTAK63-infected M2 macrophages more extensively upregulated transcripts of inflammation-related genes, TAP1, GBP1, SLAMF7, TNIP1, and IL6, and induced higher levels of cytokines related to inflammation and tissue repair, MCP-3 and EGF, as compared to BCG. Thus, our data revealed an important signature of immune responses induced in human macrophages by rBCG-LTAK63 associated with increased inflammation, activation, and tissue repair, which may be correlated with a protective immune response against TB.


  • Open Access

    Indoleamine 2,3-Dioxygenase-1 Expression is Changed During Bladder Cancer Cell Invasion

    by Hellen Joyce Sousa Pereira Santos, Luiz Henrique Gomes Matheus, Aline Silva, Stephanie Vanin Dalmazzo, Andressa Assunção Santos, Letícia Rafaela Alves Rubens Santos, Diego Mota Souza, Sabrina Thalita Reis, Ivan Pereira Nascimento, Humberto Dellê

    The severity of the bladder carcinoma (BC) is directly linked to cell invasion and metastasis. Indoleamine 2,3-dioxygenase-1 (IDO-1) is an INF-γ-induced immunomodulating enzyme that has been linked to the cancer cell invasiveness. Because IDO1 is variable among the tumors, we analyzed its expression in the BC invasion using BC mice models and cell culture. MB49 cells were orthotopically or ectopically inoculated in C57Bl6 mice to evaluate IDO1 by immunohistochemistry. For in vitro experiments, expression of IDO1 and INF-γ was evaluated in grade-1 (RT4) and in grade-3 (T24) BC cell lines. Invading and non-invading T24 cells were separated using the Matrigel/Transwell system, of which total RNA was extracted immediately or after 2 weeks of subculture. Finally, IDO1 was silenced in T24 cells to verify its role on cell invasiveness. In both animal models, IDO1 was differentially expressed between non-invading and invading cells. In cell culture, T24 cells expressed more IDO1 than RT4 cells, independently of the INF-γ expression. IDO1 was differentially expressed between non-invading and invading T24 cells, a difference that was lost by long-time subculture. IDO1 silencing resulted in diminished cell invasiveness. In conclusion, IDO1 expression is changed during bladder carcinoma invasion, playing an important role in this process.


  • Open Access

    Characterisation of alternative expression vectors for recombinant Bacillus Calmette-Guérin as live bacterial delivery systems

    by Larissa V Nascimento, Carina C Santos, Luciana Cc Leite, Ivan P Nascimento

    Pioneering research in the genetic manipulation of Mycobacterium, such as performed by Jacobs Jr et al. allowed the introduction of foreign DNA into Mycobacterium smegmatis and BCG.11 This opened the possibility for development of multi-vaccines based on BCG as a live vehicle to present heterologous antigens from different pathogens. Since then, several groups have had success in the development of rBCG strains, expressing antigens from virus, bacteria or parasites, or even cytokine molecules.1,2,12 Despite several reports on the successful construction of rBCG strains, many rBCG constructs did not attain expression, revealing the importance of characterising other expression vectors construct. On the other hand, there are studies that have indicated a role for antigen expression level in the induction of immune responses. For the Mycobacterium tuberculosis (Mtb) antigen, 85B, low-level expression skewed the immune response towards a T helper 1 (Th1) immune response, and higher expression levels towards a Th2 immune response.13


  • Open Access

    Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria

    by Carina Carvalho Dos Santos, Dunia Rodriguez, Alex Kanno Issamu, Luciana Cezar De Cerqueira Leite, Ivan Pereira Nascimento

    The development of more effective vaccines against Mycobacterium tuberculosis has become a world priority. Previously, we have shown that a recombinant BCG expressing the LTAK63 adjuvant (rBCG-LTAK63) displayed higher protection than BCG against tuberculosis challenge in mice. In order to elucidate the immune effector mechanisms induced by rBCG-LTAK63, we evaluated the immune response before and after challenge. The potential to induce an innate immune response was investigated by intraperitoneal immunization with BCG or rBCG-LTAK63: both displayed increased cellular infiltration in the peritoneum with high numbers of neutrophils at 24 h and macrophages at 7 d. The rBCG-LTAK63-immunized mice displayed increased production of Nitric Oxide at 24 h and Hydrogen Peroxide at 7 d. The number of lymphocytes was higher in the rBCG-LTAK63 group when compared to BCG. Immunophenotyping of lymphocytes showed that rBCG-LTAK63 immunization increased CD4+ and CD8+ T cells. An increased long-term Th1/Th17 cytokine profile was observed 90 d after subcutaneous immunization with rBCG-LTAK63. The evaluation of immune responses at 15 d after challenge showed that rBCG-LTAK63-immunized mice displayed increased TNF-α-secreting CD4+ T cells and multifunctional IL-2+ TNF-α+ CD4+ T cells as compared to BCG-immunized mice. Our results suggest that immunization with rBCG-LTAK63 induces enhanced innate and long-term immune responses as compared to BCG. These results can be correlated with the superior protection induced against TB.


  • Open Access

    In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment

    by Dunia Rodriguez, Cibelly Goulart, Ana C. Pagliarone, Eliane P. Silva, Priscila S. Cunegundes, Ivan P. Nascimento, Ricardo C. Borra, Waldely O. Dias, Aldo Tagliabue, Diana Boraschi, et al.

    The live attenuated mycobacterial strain BCG, in use as vaccine against tuberculosis, is considered the gold standard for primary therapy of carcinoma in situ of the bladder. Despite its limitations, to date it has not been surpassed by any other treatment. Our group has developed a recombinant BCG strain expressing the detoxified S1 pertussis toxin (rBCG-S1PT) that proved more effective than wild type BCG (WT-BCG) in increasing survival time in an experimental mouse model of bladder cancer, due to the well-known adjuvant properties of pertussis toxin. Here, we investigated the capacity of rBCG-S1PT to stimulate human immune responses, in comparison to WT-BCG, using an in vitro stimulation assay based on human whole blood cells that allows for a comprehensive evaluation of leukocyte activation. Blood leukocytes stimulated with rBCG-S1PT produced increased levels of IL-6, IL-8 and IL-10 as compared to WT-BCG, but comparable levels of IL-1, IL-2, IFN- and TNF-. Stimulation of blood cells with the recombinant BCG strain also enhanced the expression of CD25 and CD69 on human CD4+ T cells. PBMC stimulated with rBCG-S1PT induced higher cytotoxicity to MB49 bladder cancer cells than WT-BCG-stimulated PBMC. These results suggest that the rBCG-S1PT strain is able to activate an immune response in human leukocytes that is higher than that induced by WT-BCG for parameters linked to better prognosis in bladder cancer (regulation of immune and early inflammatory responses), while fully comparable to WT-BCG for classical inflammatory parameters. This establishes rBCG-S1PT as a new highly effective candidate as immunotherapeutic agent against bladder cancer.


  • Open Access

    A Bivalent RecombinantMycobacterium bovisBCG Expressing the S1 Subunit of the Pertussis Toxin Induces a Polyfunctional CD4+T Cell Immune Response

    by Alex I. Kanno, Cibelly Goulart, Luciana C. C. Leite, Ana C. Pagliarone, Ivan P. Nascimento

    Background. A recombinant BCG strain expressing the genetically detoxified S1 subunit of pertussis toxin 9K/129G (rBCG-S1PT), previously constructed by our research group, demonstrated the ability to develop high protection in mouse models of pertussis challenge which correlated with the induction of a Th1 immune response pattern. The Th1 immune response induced by rBCG-S1PT treatment was also confirmed in the murine orthotopic bladder cancer model, in which the intravesical instillation of rBCG-S1PT resulted in an improved antitumor effect. Based on these observations, we hypothesize that the reengineering of the S1PT expression in BCG could increase the efficiency of the protective Th1 immune response in order to develop a new alternative of immunotherapy in bladder cancer treatment.Objectives. To construct rBCG strains expressing S1PT from extrachromosomal (rBCG-S1PT) and integrative vectors (rBCG-Sli), or their combination, generating the bivalent strain (rBCG-S1+S1i), and to evaluate the respective immunogenicity of rBCG strains in mice.Methods. Mycobacterial plasmids were constructed by cloning thes1ptgene under integrative and extrachromosomal vectors and used to transform BCG, individually or in combination. Antigen expression and localization were confirmed by Western blot. Mice were immunized with wild-type BCG or the rBCG strains, and cytokines quantification and flow cytometry analysis were performed in splenocytes culture stimulated with mycobacterial-specific proteins.Findings. S1PT expression was confirmed in all rBCG strains. The extrachromosomal vector directs S1PT to the cell wall-associated fraction, while the integrative vector directs its expression mainly to the intracellular fraction. Higher levels of IFN-γwere observed in the splenocytes culture from the group immunized with rBCG-S1i in comparison to BCG or rBCG-S1PT. rBCG-S1+S1i showed higher levels of CD4+IFN-γ+and double-positive CD4+IFN-γ+TNF-α+T cells.Conclusions. rBCG-S1+S1i was able to express the two forms of S1PT and elicited higher induction of polyfunctional CD4+T cells, indicating enhanced immunogenicity and suggesting its use as immunotherapy for bladder cancer.


  • Generation of recombinant bacillus Calmette–Guérin and Mycobacterium smegmatis expressing BfpA and intimin as vaccine vectors against enteropathogenic Escherichia coli

    by Halyka Luzorio Franzotti Vasconcellos, Karina Scaramuzzi, Ivan Pereira Nascimento, Jorge M. Da Costa Ferreira, Cecilia M. Abe, Roxane M.F. Piazza, Andre Kipnis, Wilmar Dias da Silva


  • MPT-51/CpG DNA vaccine protects mice against Mycobacterium tuberculosis

    by Bruna Daniella de Souza Silva, Ediane Batista da Silva, Ivan Pereira Do Nascimento, Michelle Cristina Guerreiro dos Reis, André Kipnis, Ana Paula Junqueira-Kipnis


  • Open Access

    Searching Genes Encoding Leishmania Antigens for Diagnosis and Protection

    by Manuel Soto, Laura Ramírez, Miguel A. Pineda, Victor M. González, Petter F. Entringer, Camila Indiani de Oliveira, Ivan P. Nascimento, Ana P. Souza, Laura Corvo, Carlos Alonso, et al.

    Leishmaniases are a wide spectrum of parasitic diseases caused by the infection of different species of the genus Leishmania. Currently, these diseases are one of the most neglected diseases threatening 350 million people in different countries around the world. Thus, these diseases require better screening, diagnostics and treatment. An effective vaccine, that is not currently available, would be the best way to confront leishmaniases. In the past 20 years the molecular characterization of Leishmania genes encoding parasite antigens has been carried out. In this review we summarize the most common strategies employed for the isolation and characterization of genes encoding Leishmania antigens. To provide a collective view, we also discuss the results related with diagnosis and protection based on different recombinant DNA-derived Leishmania products.


  • Characterization and immunolocalization of an NTP diphosphohydrolase of Trypanosoma cruzi

    by Juliana L.R. Fietto, Ricardo DeMarco, Ivan P. Nascimento, Ieso M. Castro, Técia M.U. Carvalho, Wanderley de Souza, Maria T. Bahia, Maria J.M. Alves, Sergio Verjovski-Almeida